Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood-brain barrier and enhance neurogenesis
Cunnane SC, Trushina E, Morland C, Prigione A, Casadesus G, Andrews ZB, Beal MF, Bergersen LH, Brinton RD, de la Monte S, Eckert A, Harvey J, Jeggo R, Jhamandas JH, Kann O, la Cour CM, Martin WF, Mithieux G, Moreira PI, Murphy MP, Nave KA, Nuriel T, Oliet SHR, Saudou F, Mattson MP, Swerdlow RH, Millan MJ
Anti protease degradation Structural modification reduces its sensitivity to proteases, prolongs its half-life, and prolongs its duration of action
2013 Sep;28(6):551-9
Liquidambaric acid inhibits the proliferation of hepatocellular carcinoma cells by targeting PPAR-RXR to down-regulate fatty acid metabolism
US$ 29.86
US$ 20.65
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 24.50
